

Disease State	Probe	Test Code (TC Only)
Gastric Cancer	17q (HER2)	A428-5
Lymphoma - Burkitt	t(8;14)	B349-2
	MYC BA	J144-7
Lung Cancer	2p23 (ALK)	B236-1
	6q22 (ROS1)	B337-7
	7q31 (MET)	B336-9
Lymphoma - Diffuse Large B-Cell	3q27	B348-4
Lymphoma - Follicular	t(14;18)	B350-0
Lymphoma - Mantle Cell	t(11;14) & +11	A873-2
Lymphoma - Anaplastic Large Cell	2p23 (ALK)	B236-1
MDS	-5/5q-, -7/7q-, 8+, 20q- Panel	P960-8
	-5/5q	A869-1
	-7/7q-	A868-2
	+8	A870-8
	20q	A871-6
Myeloid Neoplasm with PDGFRB	PDGFRB	T782-2
Plasma Cell Myeloma	13q14 del, t(11;14) & +11, 17p13, t(4;14), 1q21, t(14;16) –Panel	P961-6
	13q14	A872-4
	t(11;14) & +11	A873-2
	17q13	A874-0
	t(4;14)	A875-7
	1q21	A876-5
	t(14;16)	B760-0
	t(14;20)	TB61-7
Prostate Cancer	PTEN*	J843-4


* Requires H&E with tumor demarcated by sending pathologist

REFERENCES

- Chang H, Qi X, Youg T, et al. Multiple myeloma patients with CKS1B gene amplification have a shorter progression-free survival post-autologous stem cell transplantation. *Br J Haematol.* 135(4):486-491, 2006.
- Chesi M, Nardini E, Lim RS, et al. The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts. *Blood.* 1998 Nov 1;92(9):3025-34.
- Cuneo A, Biboni R, Rigolin GM, et al. Late appearance of the 11q22.3-23.1 deletion involving the ATM locus in B-cell chronic lymphocytic leukemia and related disorders. *Clinico-biologic significance. Haematologica* 87(1):44-51,2002.
- Dohner H, Stilgenbaur S, James MR, et al. 11q deletions identify a new subset of B-cell chronic lymphocytic leukemia characterized by extensive nodal involvement and inferior prognosis. *Blood* 89:2516-2522,1997.
- Fisher, C. The diversity of soft tissue tumours with EWSR1 gene rearrangement: a review. *Histopathology* 64:134-150, 2014.
- Heim S and Mitelman F. *Cancer Cytogenetics*, 3rd edition, Wiley-Blackwell, A John Wiley & Sons, INC 2009.
- Hogan WJ, Tefferi A, Borell TJ, Jenkins R, Li CY, Witzig TE. Prognostic significance of monosomy at the 13q14 locus detected by fluorescence in situ hybridization in B-cell chronic lymphocytic leukemia. *Cancer Genet Cytogenet.* 110:77-81, 1999.
- Horn, H. Fluorescent in situ analysis of soft tissue tumor associated genetic alterations in formalin-fixed paraffin-embedded tissue. *Pathology –Research and Practice* 210 (2014) 804-811.
- Horn L, Pao W. EML4-ALK: honing in on a new target in non-small-cell lung cancer. *J Clin Oncol.* 2009 Sep 10;27(26):4232-5.
- Jenkins RB, Blair H, Ballman KV, et al. A t(1;19)(q10;p10) Mediates the Combined Deletions of 1p and 19q and Predicts a Better Prognosis of Patients with Oligodendroglioma. *Cancer Research* 66(20):9852-9861,2006
- Klein U, Jauch A, Hielscher T, et al. Chromosomal Aberrations +1q21 and del(17p13) Predict Survival in Patients With Recurrent Multiple Myeloma Treated With Lenalidomide and Dexamethasone.
- Nishida K, Tamura A, Nakazawa N, et al. The IgH heavy chain gene is frequently involved in chromosomal translocations in multiple myeloma and plasma cell leukemia as detected by in situ hybridization. *Blood* 15:90(2):526-34.
- Sasaki T, Rodig SJ, Chirieac LR, et al. The biology and treatment of EML4-ALK non-small cell lung cancer. *Eur J Cancer.* 2010 Jul;46(10):1773-80.
- Secker-Walker LM, Moorman AV, Bain BJ, Mehta AB. Secondary acute leukemia and myelodysplastic syndrome with 11q23 abnormalities. *EU Concerted Action11q23 Workshop. Leukemia* 12:840-844, 1998.
- Tefferi, Patnaik MM, Pardanani A. Eosinophilia: secondary, clonal, and idiopathic. *Br J Haematol.* 133(5):468-492, 2006.
- Varella-Garcia M, Akduman B, Sunpaweravong P, Di Maria MV, Crawford ED. The UroVysion fluorescence in situ hybridization assay is an effective tool for monitoring recurrence of bladder cancer. *Urol Oncol.* 22(1):16-19, 2004.
- Ware PL, Snow AN, Gvalani M, et al. MDM2 Copy Numbers in Well-Differentiated and Dedifferentiated Liposarcoma. *Am J Clin Pathol* 2014;141:334-341.
- Wolff, et al. 2013 ASCO/CAP HER2 Testing Guideline Update: Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer. *Arch Pathol Lab Med.* doi: 10.5858/arpa.2013-0953-SA.
- World Health Organization Classification of Tumors. *Tumors of Haematopoietic and Lymphoid Tissues*, IARC Press, Lyon, France, 2008.
- Yoshida A, Kohno T, Tsuta K, et al. ROS1-Rearranged Lung Cancer. *American Journal of Surgical Pathology* 2013, 37(4):554-562.
- Zucali PA, Ruiz MG, Giovannetti E, et al. Role of cMET expression in non-small cell lung cancer patients treated with EGFR tyrosine kinase inhibitors. *Annals of Oncology* 2008;19:1605-1612.



A business unit of BioReference Laboratories, Inc.



FISH Probe Library

FISH Probes & Panels by Disease State
HEMATOLOGIC MALIGNANCIES

1- Acute Lymphocytic Leukemia (ALL)

ALL Prognostic Panel: t(9;22), 11q23 Test Code: P260-3

Disease State	Probe	Location	Clinical Utility	Test Code
Precursor B-cell Lymphoblastic Leukemia/Lymphoma	BCR/ABL1	t(9;22)	Diagnostic, Prognostic - Poor	5265-4
	MLL	11q23	Prognostic - Poor	5427-0

2- Acute Myeloid Leukemia (AML)

AML Comprehensive Diagnostic Panel: t(9;22), 11q23, t(8;21), t(15;17), inv(16) Test Code: P261-1

Disease State	Probe	Location	Clinical Utility	Test Code
AML with t(8;21)(q22;q22); RUNX1-RUNX1T1 (AML-M2)	AML1/ETO	t(8;21)	Diagnostic, Prognostic - Favorable	5024-5
Acute Promyelocytic Leukemia with t(15;17)(q22;q12); PML-RARA (AML-M3)	PML/RARA	t(15;17)	Diagnostic, Therapeutic - Favorable	5260-5
	RARA BA	17q21	Diagnostic, Therapeutic - Favorable	J157-9
AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFβ-MYH11 (AML-M4Eo)	CBFβ	inv(16)	Diagnostic, Prognostic - Favorable	5025-2
Acute Myelomonocytic Leukemia (AML-M4) and Acute Monocytic Leukemia (AML-M5)	MLL	11q23	Diagnostic, Prognostic - Poor	5427-0
AML, BCR/ABL1	BCR/ABL1	t(9;22)	Diagnostic, Prognostic - Poor	5265-4

3- Chronic Lymphocytic Leukemia (CLL)

CLL Prognostic Panel: +12, 13q14.3, 17q13, 11q22 Test Code: 5280-3

Disease State	Probe	Location	Clinical Utility	Test Code
Chronic Lymphocytic Leukemia	Trisomy 12	+12	Prognostic - Intermediate	B513-3
	D13S319	13q14.3	Prognostic - Poor	B510-9
	RB1	13q14	Prognostic - Poor	B511-7
	ATM	11q22.3	Prognostic - Poor	B512-5
	p53	17p13	Prognostic - Poor	A314-7

4- Chronic Myeloid Disorders (CMD)

Non-CML MPN, including Primary Myelofibrosis and Mixed MPN/MDS: -5/5q-, -7/7q-, +8, 20q12 Test Code: 5281-1

Disease State	Probe	Location	Clinical Utility	Test Code
Chronic Myelogenous Leukemia (CML)	BCR/ABL1	t(9;22)	Diagnostic	5265-4
Myelodysplastic Syndrome (MDS)	-5/5q-	5q33-q34	Diagnostic, Prognostic Favorable, Therapeutic	B507-5
	-7/7q-	7q31	Diagnostic	B506-7
	Trisomy 8	+8	Diagnostic	B514-1
	20q12	del(20q)	Diagnostic	B508-3
	p53	17p13	Prognostic - Poor	A314-7
Chronic Eosinophilic Leukemia	PDGFR alpha	4q12	Diagnostic	5182-1
Myeloid Neoplasm with PDGFRB	PDGFRB	5q32	Diagnostic	T781-4

5- Non-Hodgkin Lymphomas (NHL)

Non-Hodgkin Lymphoma Panel: t(11;14), t(14;18), 3q27 Test Code: 5273-8
Diffuse Large B-Cell Lymphoma Panel (DLBCL): 8q24, t(14;18), 3q27 Test Code: L218-7 - To assess "double hit" lymphoma

Disease State	Probe	Location	Clinical Utility	Test Code
Anaplastic Large Cell Lymphoma (ALCL)	ALK	2p23	Prognostic - Favorable, Therapeutic	B684-2
Diffuse Large B-Cell Lymphoma (DLBCL)	BCL6	3q27	Diagnostic	5028-6
B-Cell Lymphoma	IGH	14q32	Diagnostic	5032-8
Burkitt Lymphoma	MYC/IGH	t(8;14)	Diagnostic	5027-8
	MYC BA	8q24	Diagnostic	J141-3
Follicular Lymphoma (FL)	IGH/BCL2	t(14;18)	Diagnostic	5270-4
Mantle Cell Lymphoma (MCL)	IGH/CCND1	t(11;14)	Diagnostic	5026-0

FISH Probes & Panels by Disease State
HEMATOLOGIC MALIGNANCIES CON'T

6- Plasma Cell Disorders (PCD)

Multiple Myeloma Panel: 13q14, t(11;14) & +11, 17q13, t(4;14), 1q21, t(14;16) Test Code: 5282-9

Disease State	Probe	Location	Clinical Utility	Test Code
Multiple Myeloma, MGUS	RB1	del(13q14)	Prognostic - Poor	B511-7
	IGH/CCND1	t(11;14) & +11	Prognostic - Favorable	5026-0
	p53	17p13	Prognostic - Poor	A314-7
	FGFR3/IGH	t(4;14)	Prognostic - Poor	A291-7
	CKS1B	1q21	Prognostic - Poor	B509-1
	IGH/MAF	t(14;16)	Prognostic - Poor	B546-3
	IGH/MAFB	t(14;20)	Prognostic - Poor (MM), Favorable (MGUS, SMM)	B545-5

SOLID TUMORS

Disease State	Probe	Location	Clinical Utility	Test Code
Breast Cancer & Gastric/ GEJ Cancer	HER2	17q	Therapeutic	5262-1 (Breast) A427-7 (Gastric)
Bladder Cancer (UroVysion®)	Chromosome 3 Chromosome 7 Chromosome 17 9p21	+3 +7 +17 del(9p21)	Diagnostic, Monitoring recurrence	5030-2
Gliomas	1p19q	Co-del (1p36/19q13)	Prognostic - Favorable	A311-3
Lung Cancer	EML4-ALK	2p23	Therapeutic	A241-2
	ROS1	6q22	Therapeutic	B334-4
	MET	7q31	Therapeutic	B335-1
Prostate Cancer	PTEN*	del(10q23)	Prognostic - Poor	B854-1
Sarcomas				
Alveolar Rhabdomyosarcoma	FOXO1	13q14	Diagnostic	B665-1
Ewing Sarcoma	EWSR1	22q12	Diagnostic	B556-2
Liposarcoma	MDM2	12q15	Diagnostic	B544-8
Synovial Sarcoma	SS18	18q11.2	Diagnostic	J331-0

BONE MARROW TRANSPLANT

Disease State	Probe	Location	Clinical Utility	Test Code
Bone Marrow Transplant Monitoring	X/Y	X and Y	Therapeutic	5066-6

TC (TECHNICAL ONLY) FISH PROBES ORDERABLE THROUGH STORMPATH



Disease State	Probe	Test Code (TC only)
AML	t(15;17): PML/RARA	A881-5
	t(8;21): AML/ETO	B891-3
	Inv16	J380-7
B-ALL, AML	11q23 (MLL)	B889-7
B-ALL, CML	t(9;12):BCR/ABL1	A880-7
Bladder Cancer	+3, +7, +17, 9p21 - (UroVysion®)	5249-8
Breast Cancer	17q (HER2)	5259-7
CLL	+12, 13q14.3, 17p13, 11q22.3 - Panel	P962-4
	+12	A877-3
	13q14.3	A878-1
	17q13	A874-0
	11q22.3	A879-9
	RB1	A872-4

* Requires H&E with tumor demarcated by sending pathologist